^
    Back
    Association details:
    Biomarker:PLK4 expression
    Cancer:Diffuse Large B Cell Lymphoma
    Drug:ocifisertib (CFI-400945) (PLK4 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    ASH 2019
    Title:

    Targeting Polo-like Kinase 4 for Therapeutic Benefit in the Patients with Diffuse Large B-Cell Lymphoma

    Published date:
    11/06/2019
    Excerpt:
    In summary, our data indicates that PLK4 is aberrantly expressed in DLBCL cell lines and tissues. Targeting PLK4 with the selective inhibitor CFI-400945 suppresses cell proliferation and induces apoptotic deaths and causes DNA damage in vitro. Our findings established PLK4 as a potential therapeutic target in DLBCL.
    DOI:
    10.1182/blood-2019-129548